Orchard Therapeutics plc conducts research and development of gene therapies, including clinical trials for genetic and other severe diseases. The company develops and provides gene therapies for rare inherited diseases, with a portfolio that includes Strimvelis and clinical-stage programs for metachromatic leukodystrophy (MLD), Wiskott-Aldrich syndrome (WAS), beta thalassemia, and mucopolysaccharidosis type I (MPS-I). It conducts clinical trials of investigational gene therapies for genetic and neurometabolic disorders. The company offers support services and resources for patients and healthcare providers, including medical information and adverse event reporting channels. Orchard Therapeutics collaborates with research partners and the healthcare community to advance research in hematopoietic stem cell (HSC) gene therapy. The company serves healthcare professionals, healthcare entities, and research partners in the healthcare and medical research sectors. The company was founded in 2015 and is based in London, United Kingdom.